Jump To

    Uterus endometrial and myometrial malignancies

    Background

    Total abdominal hysterectomy (TAH) is undertaken for the treatment of a number of medical conditions, ranging from prolapse of the uterus to benign or malignant lesions in the body of the uterus, cervix and/or ovaries.1-5 Obstetric removal of the uterus may occur due to intractable haemorrhage, rupture or abnormal placental implantation.5

    This protocol includes hysterectomy for endometrial and myometrial malignancies. See separate protocols for hysterectomies for invasive tumours of the cervix and benign conditions.


    Record the patient identifying information and any clinical information supplied together with the specimen description as designated on the container. See overview page for more detail on identification principles.

    • No
      • Non-routine fixation (not formalin), describe.
    • Yes
      • Special studies required, describe.
      • Ensure samples are taken prior to fixation.
    • Not performed
    • Performed, describe type and result
      • Frozen section
      • Imprints
      • Other, describe

    See general information for more detail on specimen handling procedures.

    Inspect the specimen and dictate a macroscopic description.


    External Inspection

    Orientate and identify the anatomical features of the specimen.

    Record additional orientation or designation provided by operating clinician:

    • Absent
    • Present
      • Method of designation (e.g. suture, incision)
      • Featured denoted

    Photograph the intact specimen if required.

    Describe the following features of the specimen:

    Procedure

    Record as stated by the clinician.

    • Total abdominal hysterectomy (TAH)
    • Radical hysterectomy
    • Subtotal hysterectomy
    • TAH and bilateral salpingo-oophorectomy (TAH/BSO)
    • Other, specify

    Specimen integrity

    • Intact
    • Opened, describe
    • Morcellated4, describe

    Laparoscopic specimens may be received in pieces and should be orientated where possible to resemble intact uterus.4

    Anatomical components included (more than one may apply) and specimen size (mm)

    Describe and measure the anatomical components present.1

    Refer to relevant specimen protocol(s) for more detail.

    Uterus

    • Measure in three dimensions1,6
    • Mid-line fundal-serosa to ectocervix
    • Maximum intercornual
    • Maximum anterior to posterior

    Cervix

    • Measure in two dimensions, anterior-posterior (12 to 6 o’clock) x transverse (3 to 6 o’clock ).

    Serosal surface4,6

    Describe:1

    • Normal
    • Abnormal
      • Nodules
      • Adhesions
      • Perforation present
      • Tumour present

    Uterus weight (g)1,6

    • Weight of specimen without ovaries or fallopian tubes

    Ovary1,6

    Fallopian tube(s)1

    Omentum1

    • Measure in three dimensions and describe
    • Proportion of fat replaced by tumour (%)

    Peritoneal biopsies, per site (usually received separately)1

    • Measure in three dimensions

    Other tissues

    • Measure and describe according to applicable protocol

    Dissection

    The surgical margins and any abnormal serosal surfaces of the uterus should be painted with ink to assess areas suspicious for tumour involvement.

    Upon receipt of the specimen, the uterus must be promptly opened out into two halves to ensure adequate fixation.

    The separate halves are immersed in formalin with the endometrial surfaces exposed in order to ensure adequate fixation.

    Traditionally the uterine cavity is opened coronally although in some institutions a sagittal technique is used. Whatever technique is used the key point is to remember that the method should allow for adequate examination, measurement and sampling of the tumour.

    Once the uterus is fixed and described, each half can be rotated and transversely sectioned sequentially to assess tumour penetration anteriorly and posteriorly in three dimensions.


    Internal Inspection

    Describe the cut surface appearance of the uterus including the following items4

    Tumour

    • Absent
    • Present
      • Number; if more than one tumour, designate and describe each tumour separately

    Tumour site1,6

    • Endometrium
      • Anterior
      • Posterior
      • Fundal
      • Left lateral wall
      • Right lateral wall
    • Cornual recess
      • Left
      • Right
      • Isthmus
    • Myometrium
    • Other, describe

    Tumour size (mm)

    • In three dimensions1

    Endometrial tumours should be measured superior-inferior x transverse x thickness, where thickness is total of exophytic plus endophytic tumour.1

    Tumour appearance

    • Exophytic
    • Endophytic
    • Haemorrhagic
    • Necrotic

    Myometrial invasion

    • No
    • Yes
      • Maximum depth of invasion (mm)6
      • Thickness of adjacent normal myometrium (mm)1,6
      • Minimum distance to serosal surface (mm)

    Endometrium

    • Thickness (mm)

    Other endometrial abnormalities, residual endometrium

    • Absent
    • Present, describe
      • Polyp(s)
      • Atrophy
      • Other, describe

    Distance to margins (mm)

    • Distance of tumour to the inferior surgical margin (mm)1

    Cervical involvement

    Specify if tumour is in continuity with endometrial lesion:6

    • No
    • Yes

    Measure (mm):1

    • Tumour size in three dimensions (superior-inferior x transverse x thickness where thickness is exophytic plus endophytic)1
    • Distance of tumour to inferior surgical margin1
    • Maximum depth of cervical wall invasion1
    • Thickness of uninvolved cervical wall (mm)1

    See separate protocol for invasive tumours of the cervix.

    Other abnormalities

    Leiomyomas with atypical macroscopic features require thorough sampling to exclude malignancy. See separate protocol for benign uterus for more detail.

    Retrieved from resection specimen

    • Describe site(s)
    • Number retrieved

    Separately submitted

    • For each specimen container, record specimen number and designation
    • Collective size of tissue in three dimensions (mm)
    • Number of grossly identified lymph nodes submitted
    • Maximum diameter of each (mm)

    Processing

    Dissect the specimen further and submit sections for processing according to the diagram provided.

    Submit representative sections of:

    • Cervix, including transformation zone if uninvolved, at least two blocks, one midline incision each from:
      • Anterior lip
      • Posterior lip
    • Ovaries, fallopian tube one block of right and left. More thorough sampling will be required for serous carcinoma or familial cancer syndrome specimens.
    • Submit left and right parametrium in its entirety, shave sections.
    • Tumour demonstrating deepest point of penetration, relationship with serosa and surgical margin(s)
    • Large endometrial tumour, contiguous sections containing the most inferior part of the tumour and the external cervical os (to allow microscopic confirmation of any cervical stroma involvement). If tumour is present, include closest cervical stromal margin.
    • Cornu, sections from both left and right, if involved
    • Isthmus (“lower uterine segment”), longitudinal section to exclude cervical extension of tumour.
    • Endometrium, representative sections of uninvolved background tissue

    Submit all peritoneal biopsies in their entirety, serially sectioned if >4mm (usually received separately). See also gynaecological small biopsy protocol.

    Submit all lymph nodes and identify the site of each.

    Record details of each cassette.

    An illustrated block key similar to the one provided may be useful.

    Block allocation key

    Cassette id
    Site
    No. of pieces
    A
    Anterior cervix
     
    B
    Posterior cervix
     
    C
    Left ovary and fallopian tube
     
    D
    Right ovary and fallopian tube
     
    E
    Left parametrium, shave section
     
    F
    Right parametrium, shave section
     
    G-J
    Tumour,demonstrating deepest point of penetration, relationship with serosa and/or surgical margins
     
    K-L
    Left and right cornu if involved
     
    M
    Isthmus, longitudinal section or contiguous sections to include inferior part of the tumour and cervical os
     
    N
    Background endometrium
     
     

    Acknowledgements

    Drs Kerryn Ireland-Jenkin and Marsali Newman for their contribution in reviewing and editing this protocol.


    References

    1. Mulvany N, Allen D, Narayan K and Stewart C. Endometrial cancer structured reporting protocol, The Royal College of Pathologists of Australasia, Surry Hills, NSW, 2011.
    2. Ganesan R, Singh N and McCluggage WG. Dataset for histological reporting of endometrial cancer, The Royal College of Pathologists, London, 2014.
    3. McCluggage WG, Fisher C and Hirschowitz L. Dataset for histological reporting of uterine sarcomas, The Royal College of Pathologists, London, 2011.
    4. Brown L, Andrew A, Hirschowitz L and Millan D. Tissue pathways for gynaecological pathology, The Royal College of Pathologists, London, 2008.
    5. Heatley MK (2008). Dissection and reporting of the organs of the female genital tract. J Clin Pathol 2008;61(3):241-257.

    Jump To

      Uterus 5

      Total hysterectomy and bilateral salpingo-oophorectomy for endometrial cancer

      Uterus 6

      Total hysterectomy and bilateral salpingo-oophorectomy for endometrial cancer, suggested blocks

      Uterus 1

      Uterus with endometrial tumour, received incised sagitally on the anterior aspect

      Uterus 2

      Uterus with endometrial tumour, posterior aspect

      Uterus 3

      Uterus with endometrial tumour, dissected

      Uterus 4

      Uterus with endometrial tumour


      Uterus malignant -identification

      Hysterectomy in malignant setting -identification

      RCPA | 12 October 2017

      Uterus malignant -orientation

      Hysterectomy in a malignant setting -orientation

      RCPA | 12 October 2017

      Uterus malignant -external inspection

      Hysterectomy in a malignant setting -external inspection

      RCPA | 12 October 2017

      Uterus malignant -dissection

      Hysterectomy in a malignant setting -description and dissection

      RCPA | 12 October 2017

      Page last updated:

      Copyright © 2019 RCPA. All rights reserved.

      25-Mar-2019
      Top